跳转至内容
Merck
CN

PZ0416

PF-05480090

≥98% (HPLC)

别名:

(2R,3S)-2-(4-(But-2-ynyloxy)phenylsulfonamido)-N,3-dihydroxybutanamide, (2R,3S)-2-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, (2R,3S)-2-[[[4-(2-Butyn-1-yloxy)phenyl]sulfonyl]amino]-N,3-dihydroxybutanamide, PF 05480090, PF 548, PF 5480090, PF-548, PF-5480090, PF05480090, PF548, PF5480090, TMI 002, TMI 2, TMI-002, TMI-2, TMI002, TMI2, WAY 180022, WAY 18022, WAY-180022, WAY-18022, WAY180022, WAY18022

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C14H18N2O6S
化学文摘社编号:
287406-12-6
分子量:
342.37
UNSPSC Code:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C14H18N2O6S/c1-3-4-9-22-11-5-7-12(8-6-11)23(20,21)16-13(10(2)17)14(18)15-19/h5-8,10,13,16-17,19H,9H2,1-2H3,(H,15,18)/t10-,13+/m0/s1

InChI key

VMOSDDURWLNMNG-GXFFZTMASA-N

SMILES string

C[C@@H]([C@H](C(NO)=O)NS(=O)(C1=CC=C(C=C1)OCC#CC)=O)O

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

PF-05480090 (PF-5480090; TMI-2) is an orally active, potent TACE (ADAM17) inhibitor (IC50 = 2 nM) with good selectivity over ADAM10 (IC50 = 1.09 μM), MMP-1/7 (IC50 = 2.47/0.96 μM) and MMP-8/9/13/14 (IC50 =35/ 777/96/582 nM). TMI-2 inhibits LPS-induced TNF production in cultrues (RAW/THP-1 IC50 = 200/430 nM), ex vivo (human whole blood IC50 = 1 μM) and in vivo (ED50 = 3 mg/kg; TMI-2 p.o. 1 hr prior to 40 ng LPS/mouse i.v.). TMI-2 is efficacious in a rat model of adjuvant-induced arthritis (AIA; 30 and 100 mg/kg p.o. b.i.d.) and a murine model of collagen-induced arthritis (CIA; 100 mg/kg p.o. b.i.d.).

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000140831
0000140832
0000123182

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Marta Stolarczyk et al.
American journal of physiology. Lung cellular and molecular physiology, 314(4), L555-L568 (2018-01-20)
The EGF receptor (EGFR)/a disintegrin and metalloproteinase 17 (ADAM17) signaling pathway mediates the shedding of growth factors and secretion of cytokines and is involved in chronic inflammation and tissue remodeling. Since these are hallmarks of cystic fibrosis (CF) lung disease
Marta Stolarczyk et al.
Physiological reports, 4(16) (2016-08-27)
Aberrant activity of a disintegrin and metalloprotease 17 (ADAM17), also known as TACE, and epidermal growth factor receptor (EGFR) has been suggested to contribute to chronic obstructive pulmonary disease (COPD) development and progression. The aim of this study was to
Mengcheng Shen et al.
Circulation research, 123(3), 372-388 (2018-06-23)
ADAM17 (a disintegrin and metalloproteinase-17) is a membrane-bound enzyme that regulates bioavailability of multiple transmembrane proteins by proteolytic processing. ADAM17 has been linked to several pathologies, but its role in thoracic aortic aneurysm (TAA) has not been determined. The objective
Amy W Ku et al.
eLife, 5 (2016-12-09)
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues where MDSC co-mingle with T cells. Here we show that
Yuhua Zhang et al.
International immunopharmacology, 4(14), 1845-1857 (2004-11-09)
TNF-alpha converting enzyme (TACE) is a validated therapeutic target for the development of oral tumor necrosis factor-alpha (TNF-alpha) inhibitors. Here we report the pre-clinical results and characterization of a selective and potent TACE inhibitor, (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide (TMI-2), in various in
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持